

**Lansoprazole oro-dispersible tablet 15 mg, 30 mg  
(Zoton FasTab)**

**(No: 229/05)**

**Wyeth**

**Product Update**

9 December 2005

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**Lansoprazole oro-dispersible tablet (Zoton FasTab<sup>®</sup>)** is accepted for use in NHS Scotland, in combination with appropriate antibiotics, for the eradication of *Helicobacter pylori* from the upper gastrointestinal tract in patients with ulcer-like dyspepsia in whom *Helicobacter pylori* infection has been demonstrated.

The standard formulation of lansoprazole also has this indication.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 11 October 2005.*

**Chairman  
Scottish Medicines Consortium**